Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease

Background: Rapidly progressive interstitial lung disease (RP-ILD) is a frequent and severe manifestation of anti-MDA5 dermatomyositis (MDA5-DM) associated with poor outcome. The optimal treatment regimen for MDA5-DM RP-ILD is yet to be determined. Specifically, the value of adding plasma exchange (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of autoimmunity 2022-12, Vol.133
Hauptverfasser: Bay, Pierre, de Chambrun, Marc Pineton, Rothstein, Vincent, Mahevas, Matthieu, de Prost, Nicolas, Roux, Antoine, Zuber, Benjamin, Biet, Dominique Israël, Hervier, Baptiste, Tazi, Abdellatif, Mouthon, Luc, Mekinian, Arsène, Deligny, Christophe, Borie, Raphaël, Meurice, Jean Claude, Meyer, Alain, Priou, Pascaline, Savale, Laurent, de Saint Martin, Luc, Gallay, Laure, Cottin, Vincent, Blanchard, Elodie, Brillet, Pierre-Yves, Khafagy, Philippe, Benveniste, Olivier, Nunes, Hilario, Allenbach, Yves, Uzunhan, Yurdagül
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Journal of autoimmunity
container_volume 133
creator Bay, Pierre
de Chambrun, Marc Pineton
Rothstein, Vincent
Mahevas, Matthieu
de Prost, Nicolas
Roux, Antoine
Zuber, Benjamin
Biet, Dominique Israël
Hervier, Baptiste
Tazi, Abdellatif
Mouthon, Luc
Mekinian, Arsène
Deligny, Christophe
Borie, Raphaël
Meurice, Jean Claude
Meyer, Alain
Priou, Pascaline
Savale, Laurent
de Saint Martin, Luc
Gallay, Laure
Cottin, Vincent
Blanchard, Elodie
Brillet, Pierre-Yves
Khafagy, Philippe
Benveniste, Olivier
Nunes, Hilario
Allenbach, Yves
Uzunhan, Yurdagül
description Background: Rapidly progressive interstitial lung disease (RP-ILD) is a frequent and severe manifestation of anti-MDA5 dermatomyositis (MDA5-DM) associated with poor outcome. The optimal treatment regimen for MDA5-DM RP-ILD is yet to be determined. Specifically, the value of adding plasma exchange (PLEX) to corticosteroids and immunosuppressants remains unclear. We aimed to evaluate the effect of PLEX on the outcome of patients with MDA5-DM RP-ILD.Methods: This French nationwide multicentre retrospective study included all MDA5-DM RP-ILD patients from 2012 to 2021 admitted to 18 centres. The primary endpoint was one-year transplant-free survival.Results: 51 patients with MDA5-DM RP-ILD (female 67%; mean age at disease onset: 51 ± 11.6 years) were included. Thirty-two (63%) patients required mechanical ventilation and twenty-five (49%) received PLEX. One-year mortality or lung transplant occurred in 63% cases after a median follow-up of 77 [38-264] days. The Cox proportional hazards multivariable model only retained mechanical ventilation but not PLEX (p = 0.7) as independent predictor of the primary endpoint. One-year transplant-free survival rates in PLEX + vs. PLEX-were 20% vs. 54% (p = 0.01), respectively. The Kaplan-Meier estimated probabilities of one-year transplant-free survival was statistically higher in PLEX-compared to PLEX + patients (p = 0.05). PLEX + compared to PLEX-patients more frequently received mechanical ventilation and immunosuppressants suggesting PLEX + patients had a more severe disease.Conclusion: MDA5-DM RP-ILD is associated with poor rate of one-year transplant-free survival. The use of PLEX was not associated with a better outcome albeit they were mainly given to more severe patients. While our study reports the largest series of MDA5-DM RP-ILD given PLEX, these results needs to be interpreted with caution owing the numerous selection, indication and interpretation bias. Further studies are needed to evaluate their efficacy in this setting.
doi_str_mv 10.1016/j.jaut.2022.102941
format Article
fullrecord <record><control><sourceid>hal</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04482152v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_04482152v1</sourcerecordid><originalsourceid>FETCH-hal_primary_oai_HAL_hal_04482152v13</originalsourceid><addsrcrecordid>eNqVyrFOwzAQgGELUYlAeQGmWxkSfCYuyVhBUYeysUenxEkuch3Ldgt5e6jECzD90qdfiAeUBUrcPE3FRKdUKKnUL6i6xCuRoax1XqN-uRaZrOpNXpWIN-I2xklKRK11Jrpd33NL7QJzD95SPBKY73YkNxhgB54SG5cifHEagVzi_ONtqyGQ584u4MM8BBMjny97MiEmTkwW7MkN0HE0FM1arHqy0dz_9U48vu8-X_f5SLbxgY8UlmYmbvbbQ3MxWZaVQq3O-Pyf9wcVn1H6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease</title><source>Elsevier ScienceDirect Journals</source><creator>Bay, Pierre ; de Chambrun, Marc Pineton ; Rothstein, Vincent ; Mahevas, Matthieu ; de Prost, Nicolas ; Roux, Antoine ; Zuber, Benjamin ; Biet, Dominique Israël ; Hervier, Baptiste ; Tazi, Abdellatif ; Mouthon, Luc ; Mekinian, Arsène ; Deligny, Christophe ; Borie, Raphaël ; Meurice, Jean Claude ; Meyer, Alain ; Priou, Pascaline ; Savale, Laurent ; de Saint Martin, Luc ; Gallay, Laure ; Cottin, Vincent ; Blanchard, Elodie ; Brillet, Pierre-Yves ; Khafagy, Philippe ; Benveniste, Olivier ; Nunes, Hilario ; Allenbach, Yves ; Uzunhan, Yurdagül</creator><creatorcontrib>Bay, Pierre ; de Chambrun, Marc Pineton ; Rothstein, Vincent ; Mahevas, Matthieu ; de Prost, Nicolas ; Roux, Antoine ; Zuber, Benjamin ; Biet, Dominique Israël ; Hervier, Baptiste ; Tazi, Abdellatif ; Mouthon, Luc ; Mekinian, Arsène ; Deligny, Christophe ; Borie, Raphaël ; Meurice, Jean Claude ; Meyer, Alain ; Priou, Pascaline ; Savale, Laurent ; de Saint Martin, Luc ; Gallay, Laure ; Cottin, Vincent ; Blanchard, Elodie ; Brillet, Pierre-Yves ; Khafagy, Philippe ; Benveniste, Olivier ; Nunes, Hilario ; Allenbach, Yves ; Uzunhan, Yurdagül</creatorcontrib><description>Background: Rapidly progressive interstitial lung disease (RP-ILD) is a frequent and severe manifestation of anti-MDA5 dermatomyositis (MDA5-DM) associated with poor outcome. The optimal treatment regimen for MDA5-DM RP-ILD is yet to be determined. Specifically, the value of adding plasma exchange (PLEX) to corticosteroids and immunosuppressants remains unclear. We aimed to evaluate the effect of PLEX on the outcome of patients with MDA5-DM RP-ILD.Methods: This French nationwide multicentre retrospective study included all MDA5-DM RP-ILD patients from 2012 to 2021 admitted to 18 centres. The primary endpoint was one-year transplant-free survival.Results: 51 patients with MDA5-DM RP-ILD (female 67%; mean age at disease onset: 51 ± 11.6 years) were included. Thirty-two (63%) patients required mechanical ventilation and twenty-five (49%) received PLEX. One-year mortality or lung transplant occurred in 63% cases after a median follow-up of 77 [38-264] days. The Cox proportional hazards multivariable model only retained mechanical ventilation but not PLEX (p = 0.7) as independent predictor of the primary endpoint. One-year transplant-free survival rates in PLEX + vs. PLEX-were 20% vs. 54% (p = 0.01), respectively. The Kaplan-Meier estimated probabilities of one-year transplant-free survival was statistically higher in PLEX-compared to PLEX + patients (p = 0.05). PLEX + compared to PLEX-patients more frequently received mechanical ventilation and immunosuppressants suggesting PLEX + patients had a more severe disease.Conclusion: MDA5-DM RP-ILD is associated with poor rate of one-year transplant-free survival. The use of PLEX was not associated with a better outcome albeit they were mainly given to more severe patients. While our study reports the largest series of MDA5-DM RP-ILD given PLEX, these results needs to be interpreted with caution owing the numerous selection, indication and interpretation bias. Further studies are needed to evaluate their efficacy in this setting.</description><identifier>ISSN: 0896-8411</identifier><identifier>EISSN: 1095-9157</identifier><identifier>DOI: 10.1016/j.jaut.2022.102941</identifier><language>eng</language><publisher>Elsevier</publisher><subject>Humanities and Social Sciences ; Life Sciences</subject><ispartof>Journal of autoimmunity, 2022-12, Vol.133</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-6751-2110 ; 0000-0002-7020-1954 ; 0000-0002-5591-0955 ; 0000-0002-2411-5545 ; 0000-0002-9838-246X ; 0000-0003-2849-3049 ; 0000-0003-2849-3049 ; 0000-0002-2411-5545 ; 0000-0002-6751-2110 ; 0000-0002-9838-246X ; 0000-0002-7020-1954 ; 0000-0002-5591-0955</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://hal.science/hal-04482152$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Bay, Pierre</creatorcontrib><creatorcontrib>de Chambrun, Marc Pineton</creatorcontrib><creatorcontrib>Rothstein, Vincent</creatorcontrib><creatorcontrib>Mahevas, Matthieu</creatorcontrib><creatorcontrib>de Prost, Nicolas</creatorcontrib><creatorcontrib>Roux, Antoine</creatorcontrib><creatorcontrib>Zuber, Benjamin</creatorcontrib><creatorcontrib>Biet, Dominique Israël</creatorcontrib><creatorcontrib>Hervier, Baptiste</creatorcontrib><creatorcontrib>Tazi, Abdellatif</creatorcontrib><creatorcontrib>Mouthon, Luc</creatorcontrib><creatorcontrib>Mekinian, Arsène</creatorcontrib><creatorcontrib>Deligny, Christophe</creatorcontrib><creatorcontrib>Borie, Raphaël</creatorcontrib><creatorcontrib>Meurice, Jean Claude</creatorcontrib><creatorcontrib>Meyer, Alain</creatorcontrib><creatorcontrib>Priou, Pascaline</creatorcontrib><creatorcontrib>Savale, Laurent</creatorcontrib><creatorcontrib>de Saint Martin, Luc</creatorcontrib><creatorcontrib>Gallay, Laure</creatorcontrib><creatorcontrib>Cottin, Vincent</creatorcontrib><creatorcontrib>Blanchard, Elodie</creatorcontrib><creatorcontrib>Brillet, Pierre-Yves</creatorcontrib><creatorcontrib>Khafagy, Philippe</creatorcontrib><creatorcontrib>Benveniste, Olivier</creatorcontrib><creatorcontrib>Nunes, Hilario</creatorcontrib><creatorcontrib>Allenbach, Yves</creatorcontrib><creatorcontrib>Uzunhan, Yurdagül</creatorcontrib><title>Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease</title><title>Journal of autoimmunity</title><description>Background: Rapidly progressive interstitial lung disease (RP-ILD) is a frequent and severe manifestation of anti-MDA5 dermatomyositis (MDA5-DM) associated with poor outcome. The optimal treatment regimen for MDA5-DM RP-ILD is yet to be determined. Specifically, the value of adding plasma exchange (PLEX) to corticosteroids and immunosuppressants remains unclear. We aimed to evaluate the effect of PLEX on the outcome of patients with MDA5-DM RP-ILD.Methods: This French nationwide multicentre retrospective study included all MDA5-DM RP-ILD patients from 2012 to 2021 admitted to 18 centres. The primary endpoint was one-year transplant-free survival.Results: 51 patients with MDA5-DM RP-ILD (female 67%; mean age at disease onset: 51 ± 11.6 years) were included. Thirty-two (63%) patients required mechanical ventilation and twenty-five (49%) received PLEX. One-year mortality or lung transplant occurred in 63% cases after a median follow-up of 77 [38-264] days. The Cox proportional hazards multivariable model only retained mechanical ventilation but not PLEX (p = 0.7) as independent predictor of the primary endpoint. One-year transplant-free survival rates in PLEX + vs. PLEX-were 20% vs. 54% (p = 0.01), respectively. The Kaplan-Meier estimated probabilities of one-year transplant-free survival was statistically higher in PLEX-compared to PLEX + patients (p = 0.05). PLEX + compared to PLEX-patients more frequently received mechanical ventilation and immunosuppressants suggesting PLEX + patients had a more severe disease.Conclusion: MDA5-DM RP-ILD is associated with poor rate of one-year transplant-free survival. The use of PLEX was not associated with a better outcome albeit they were mainly given to more severe patients. While our study reports the largest series of MDA5-DM RP-ILD given PLEX, these results needs to be interpreted with caution owing the numerous selection, indication and interpretation bias. Further studies are needed to evaluate their efficacy in this setting.</description><subject>Humanities and Social Sciences</subject><subject>Life Sciences</subject><issn>0896-8411</issn><issn>1095-9157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqVyrFOwzAQgGELUYlAeQGmWxkSfCYuyVhBUYeysUenxEkuch3Ldgt5e6jECzD90qdfiAeUBUrcPE3FRKdUKKnUL6i6xCuRoax1XqN-uRaZrOpNXpWIN-I2xklKRK11Jrpd33NL7QJzD95SPBKY73YkNxhgB54SG5cifHEagVzi_ONtqyGQ584u4MM8BBMjny97MiEmTkwW7MkN0HE0FM1arHqy0dz_9U48vu8-X_f5SLbxgY8UlmYmbvbbQ3MxWZaVQq3O-Pyf9wcVn1H6</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Bay, Pierre</creator><creator>de Chambrun, Marc Pineton</creator><creator>Rothstein, Vincent</creator><creator>Mahevas, Matthieu</creator><creator>de Prost, Nicolas</creator><creator>Roux, Antoine</creator><creator>Zuber, Benjamin</creator><creator>Biet, Dominique Israël</creator><creator>Hervier, Baptiste</creator><creator>Tazi, Abdellatif</creator><creator>Mouthon, Luc</creator><creator>Mekinian, Arsène</creator><creator>Deligny, Christophe</creator><creator>Borie, Raphaël</creator><creator>Meurice, Jean Claude</creator><creator>Meyer, Alain</creator><creator>Priou, Pascaline</creator><creator>Savale, Laurent</creator><creator>de Saint Martin, Luc</creator><creator>Gallay, Laure</creator><creator>Cottin, Vincent</creator><creator>Blanchard, Elodie</creator><creator>Brillet, Pierre-Yves</creator><creator>Khafagy, Philippe</creator><creator>Benveniste, Olivier</creator><creator>Nunes, Hilario</creator><creator>Allenbach, Yves</creator><creator>Uzunhan, Yurdagül</creator><general>Elsevier</general><scope>1XC</scope><scope>BXJBU</scope><orcidid>https://orcid.org/0000-0002-6751-2110</orcidid><orcidid>https://orcid.org/0000-0002-7020-1954</orcidid><orcidid>https://orcid.org/0000-0002-5591-0955</orcidid><orcidid>https://orcid.org/0000-0002-2411-5545</orcidid><orcidid>https://orcid.org/0000-0002-9838-246X</orcidid><orcidid>https://orcid.org/0000-0003-2849-3049</orcidid><orcidid>https://orcid.org/0000-0003-2849-3049</orcidid><orcidid>https://orcid.org/0000-0002-2411-5545</orcidid><orcidid>https://orcid.org/0000-0002-6751-2110</orcidid><orcidid>https://orcid.org/0000-0002-9838-246X</orcidid><orcidid>https://orcid.org/0000-0002-7020-1954</orcidid><orcidid>https://orcid.org/0000-0002-5591-0955</orcidid></search><sort><creationdate>202212</creationdate><title>Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease</title><author>Bay, Pierre ; de Chambrun, Marc Pineton ; Rothstein, Vincent ; Mahevas, Matthieu ; de Prost, Nicolas ; Roux, Antoine ; Zuber, Benjamin ; Biet, Dominique Israël ; Hervier, Baptiste ; Tazi, Abdellatif ; Mouthon, Luc ; Mekinian, Arsène ; Deligny, Christophe ; Borie, Raphaël ; Meurice, Jean Claude ; Meyer, Alain ; Priou, Pascaline ; Savale, Laurent ; de Saint Martin, Luc ; Gallay, Laure ; Cottin, Vincent ; Blanchard, Elodie ; Brillet, Pierre-Yves ; Khafagy, Philippe ; Benveniste, Olivier ; Nunes, Hilario ; Allenbach, Yves ; Uzunhan, Yurdagül</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hal_primary_oai_HAL_hal_04482152v13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Humanities and Social Sciences</topic><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bay, Pierre</creatorcontrib><creatorcontrib>de Chambrun, Marc Pineton</creatorcontrib><creatorcontrib>Rothstein, Vincent</creatorcontrib><creatorcontrib>Mahevas, Matthieu</creatorcontrib><creatorcontrib>de Prost, Nicolas</creatorcontrib><creatorcontrib>Roux, Antoine</creatorcontrib><creatorcontrib>Zuber, Benjamin</creatorcontrib><creatorcontrib>Biet, Dominique Israël</creatorcontrib><creatorcontrib>Hervier, Baptiste</creatorcontrib><creatorcontrib>Tazi, Abdellatif</creatorcontrib><creatorcontrib>Mouthon, Luc</creatorcontrib><creatorcontrib>Mekinian, Arsène</creatorcontrib><creatorcontrib>Deligny, Christophe</creatorcontrib><creatorcontrib>Borie, Raphaël</creatorcontrib><creatorcontrib>Meurice, Jean Claude</creatorcontrib><creatorcontrib>Meyer, Alain</creatorcontrib><creatorcontrib>Priou, Pascaline</creatorcontrib><creatorcontrib>Savale, Laurent</creatorcontrib><creatorcontrib>de Saint Martin, Luc</creatorcontrib><creatorcontrib>Gallay, Laure</creatorcontrib><creatorcontrib>Cottin, Vincent</creatorcontrib><creatorcontrib>Blanchard, Elodie</creatorcontrib><creatorcontrib>Brillet, Pierre-Yves</creatorcontrib><creatorcontrib>Khafagy, Philippe</creatorcontrib><creatorcontrib>Benveniste, Olivier</creatorcontrib><creatorcontrib>Nunes, Hilario</creatorcontrib><creatorcontrib>Allenbach, Yves</creatorcontrib><creatorcontrib>Uzunhan, Yurdagül</creatorcontrib><collection>Hyper Article en Ligne (HAL)</collection><collection>HAL-SHS: Archive ouverte en Sciences de l'Homme et de la Société</collection><jtitle>Journal of autoimmunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bay, Pierre</au><au>de Chambrun, Marc Pineton</au><au>Rothstein, Vincent</au><au>Mahevas, Matthieu</au><au>de Prost, Nicolas</au><au>Roux, Antoine</au><au>Zuber, Benjamin</au><au>Biet, Dominique Israël</au><au>Hervier, Baptiste</au><au>Tazi, Abdellatif</au><au>Mouthon, Luc</au><au>Mekinian, Arsène</au><au>Deligny, Christophe</au><au>Borie, Raphaël</au><au>Meurice, Jean Claude</au><au>Meyer, Alain</au><au>Priou, Pascaline</au><au>Savale, Laurent</au><au>de Saint Martin, Luc</au><au>Gallay, Laure</au><au>Cottin, Vincent</au><au>Blanchard, Elodie</au><au>Brillet, Pierre-Yves</au><au>Khafagy, Philippe</au><au>Benveniste, Olivier</au><au>Nunes, Hilario</au><au>Allenbach, Yves</au><au>Uzunhan, Yurdagül</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease</atitle><jtitle>Journal of autoimmunity</jtitle><date>2022-12</date><risdate>2022</risdate><volume>133</volume><issn>0896-8411</issn><eissn>1095-9157</eissn><abstract>Background: Rapidly progressive interstitial lung disease (RP-ILD) is a frequent and severe manifestation of anti-MDA5 dermatomyositis (MDA5-DM) associated with poor outcome. The optimal treatment regimen for MDA5-DM RP-ILD is yet to be determined. Specifically, the value of adding plasma exchange (PLEX) to corticosteroids and immunosuppressants remains unclear. We aimed to evaluate the effect of PLEX on the outcome of patients with MDA5-DM RP-ILD.Methods: This French nationwide multicentre retrospective study included all MDA5-DM RP-ILD patients from 2012 to 2021 admitted to 18 centres. The primary endpoint was one-year transplant-free survival.Results: 51 patients with MDA5-DM RP-ILD (female 67%; mean age at disease onset: 51 ± 11.6 years) were included. Thirty-two (63%) patients required mechanical ventilation and twenty-five (49%) received PLEX. One-year mortality or lung transplant occurred in 63% cases after a median follow-up of 77 [38-264] days. The Cox proportional hazards multivariable model only retained mechanical ventilation but not PLEX (p = 0.7) as independent predictor of the primary endpoint. One-year transplant-free survival rates in PLEX + vs. PLEX-were 20% vs. 54% (p = 0.01), respectively. The Kaplan-Meier estimated probabilities of one-year transplant-free survival was statistically higher in PLEX-compared to PLEX + patients (p = 0.05). PLEX + compared to PLEX-patients more frequently received mechanical ventilation and immunosuppressants suggesting PLEX + patients had a more severe disease.Conclusion: MDA5-DM RP-ILD is associated with poor rate of one-year transplant-free survival. The use of PLEX was not associated with a better outcome albeit they were mainly given to more severe patients. While our study reports the largest series of MDA5-DM RP-ILD given PLEX, these results needs to be interpreted with caution owing the numerous selection, indication and interpretation bias. Further studies are needed to evaluate their efficacy in this setting.</abstract><pub>Elsevier</pub><doi>10.1016/j.jaut.2022.102941</doi><orcidid>https://orcid.org/0000-0002-6751-2110</orcidid><orcidid>https://orcid.org/0000-0002-7020-1954</orcidid><orcidid>https://orcid.org/0000-0002-5591-0955</orcidid><orcidid>https://orcid.org/0000-0002-2411-5545</orcidid><orcidid>https://orcid.org/0000-0002-9838-246X</orcidid><orcidid>https://orcid.org/0000-0003-2849-3049</orcidid><orcidid>https://orcid.org/0000-0003-2849-3049</orcidid><orcidid>https://orcid.org/0000-0002-2411-5545</orcidid><orcidid>https://orcid.org/0000-0002-6751-2110</orcidid><orcidid>https://orcid.org/0000-0002-9838-246X</orcidid><orcidid>https://orcid.org/0000-0002-7020-1954</orcidid><orcidid>https://orcid.org/0000-0002-5591-0955</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0896-8411
ispartof Journal of autoimmunity, 2022-12, Vol.133
issn 0896-8411
1095-9157
language eng
recordid cdi_hal_primary_oai_HAL_hal_04482152v1
source Elsevier ScienceDirect Journals
subjects Humanities and Social Sciences
Life Sciences
title Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A46%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20plasma%20exchange%20in%20patients%20with%20anti-MDA5%20rapidly%20progressive%20interstitial%20lung%20disease&rft.jtitle=Journal%20of%20autoimmunity&rft.au=Bay,%20Pierre&rft.date=2022-12&rft.volume=133&rft.issn=0896-8411&rft.eissn=1095-9157&rft_id=info:doi/10.1016/j.jaut.2022.102941&rft_dat=%3Chal%3Eoai_HAL_hal_04482152v1%3C/hal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true